ClinicalTrials.gg
RecruitingNCT07863219Updated Oct 7, 2026

Short Term Effects of a Multimodal Intervention With RGM on Cognition in People With Parkinson's Disease.

An interventional study of Ronnie Gardiner Method in Parkinson Disease (PD), Cognition and Quality of Life, sponsored by University Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University Ghent · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Parkinson Disease with a site in Belgium — 19 open to participants now, 23 under way, 2 of them phase 3. Parkinson Disease · Belgium.

Planned enrollment
57th of 65
20 · median 52
Started
2026
with 6 others
No phase
37 of 82
7 open now
Primary completion
2026-12
later than 7 of 22 live
Registered
81st of 82
by date
Lead sponsor
3 of 82
University Ghent

Among the 82 studies in Parkinson Disease with a site in Belgium, this one is the 57th largest by planned enrollment of the 65 interventional ones that give a count, is one of 7 that started in 2026, is one of 37 with no phase, reaches primary completion later than 7 of the 22 other live ones, and was the 81st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

19 of the 82 studies in Parkinson Disease with a site in Belgium are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Parkinson Disease with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the Ronnie Gardiner Method (RGM) works to improve cognitive functions in adults with Parkinson's disease (early to mid-stage). It will also learn about the secondary effects on speech, mobility, balance, and mood.

The main questions it aims to answer are:

  • Does a 10-week RGM intervention improve cognitive aspects, speech (indirectly through improved breathing), mobility, and balance in participants with Parkinson's disease?
  • How do participants experience the intensity, difficulty, and emotional impact of the RGM sessions?
Read the detailed description

The Ronnie Gardiner Method (RGM) is a cheerful, structured, multi-sensory brain exercise method that utilizes rhythm and music to stimulate movement, speech, and cognition. RGM makes playful use of rhythm, music, movement, speech, hearing, sight, and touch. During practice, the participant reads the symbols and 'translates' them into the corresponding movement, which is performed to the rhythm of the music. Preliminary research suggests RGM may have added value in promoting mobility, cognition, and well-being in neurological patients (https://www.tandfonline.com/doi/full/10.1080/09638288.2024.2392037#d1e1192).

The RGM exercise series for which participants are registering is integrated in the "Fit en Actief group classes" organized by the Ghent Flemish Parkinson League - in collaboration with Ghent University Rehabilitation Sciences and Physiotherapy.

The classes will take place from October to December 2026 (10 weeks), with exercises taking place once a week for 1.5 hours (on Thursdays) in the practical classrooms of the Rehabilitation Sciences and Physiotherapy program (UH Ghent, B3). In addition to the exercise sessions themselves, participants will be asked to perform home exercises twice a week for 15 minutes.

Before and after the exercise series, participants will be invited to take a pre- and post-test including administrative data, cognition, motor symptoms, balance, QOL. The training process (home exercises, experiences) will be inventoried by temporary questionnaires.

Afterwards, participants will be surveyed regarding changes in medication during the exercise series, changes in the frequency or content of (physio)therapy, and perceived changes in attention, memory, and planning.

03

Conditions studied

  • Parkinson Disease (PD)
  • Cognition
  • Quality of Life
  • Functional Mobility

Browse trials for

Keywords

  • Ronnie Gardiner Method
  • multimodal therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of idiopathic Parkinson's disease
  • safe, independent mobility and participation (Hoehn and Yahr stages 1-3)
  • a stable dopaminergic medication regimen for at least 4 weeks prior to study participation
  • willingness and ability to participate in a 10-week intervention program
  • willingness to participate in the study (signing of )

Exclusion criteria

Exclusion Criteria:

  • Presence of other neurological or severe psychiatric conditions that could interfere with participation or the interpretation of results (e.g., substance use disorder, severe depression, psychosis)
  • Severe visual or hearing impairments that limit the ability to follow group instructions as determined by a physician.
  • Physical limitations that inhibit safe participation in moderate-to-vigorous exercise or group rehabilitation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    RGM

    10 weeks of RGM group training (1.5h/w) supplemented with home exercises and conventional care

    Other: Ronnie Gardiner Method

Interventions

  • OtherRonnie Gardiner Method

    1. Warm-up (10 min): light rhythmic movements to music; activation of coordination and attention. 2. RGM Block 1 (30 min): cognitive-motor exercises incorporating color, sound, and movement elements (bilateral). 3. Strength or interval segment (10 min): short strength/conditioning exercises (Tabata style) alternating between 20 seconds of activity and 20 seconds of rest. The exercises focus on strengthening postural muscles, improving rotation, encouraging weight shifting, and initiating movement quickly (the 4 principles of the PWR! concept). 4. 10-minute break 5. RGM Block 2 (30 min): cognitive-motor exercises incorporating color, sound, and movement elements (bilateral). 6. Cool-down (10 min): relaxation, breathing, evaluation. Cognitive component During the sessions, executive functions, attention, and processing speed are challenged and practiced through dual-task situations, pattern recognition, and auditory response tasks. Home exercises After each session, participants are gi

    Also known as: multimodal therapy, group therapy

06

What researchers measure

Primary outcomes

  1. change in cognition

    score on SCOPA-COG

    Time frame: From enrollment to the end of intervention at 10 weeks

Secondary outcomes

  1. change in motor symptoms

    score of MDS-UPDRS III

    Time frame: From enrollment to the end of intervention at 10 weeks

  2. change in balance and mobility

    score of MiniBESTest / Functional Gait Assessment

    Time frame: From enrollment to the end of intervention at 10 weeks

  3. change in QOL

    score of PDQ39

    Time frame: From enrollment to the end of intervention at 10 weeks

  4. Speech handicap Index

    score of perceived handicap - physical, functional and emotional

    Time frame: From enrollment to the end of intervention at 10 weeks

  5. change in quality of voice (vowel formants, voice oncet time), motor speech and prosody

    Praat-score (a free, open-source computer program) Motor Speech Profile - score (vocal tremor, diadochokinetic rates, and pitch/formant transitions) Loudness, intonation and speech intelligibility during reading ("The North Wind and the Sun") - 3 minutes of spontaneous speech

    Time frame: From enrollment to the end of intervention at 10 weeks

  6. Change in maximum voluntary respiration rate

    maximum volontary respiration frequency

    Time frame: From enrollment up to 10 weeks of intervention

07

Study locations

1 of 1 sites recruiting
  • University Hospital Ghent
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Wim De Wilde, MSc · ContactWim.dewilde@ugent.be · +32 472 57 58 08
    • Sanne Stegen, dr. · Contactsanne.stegen@ugent.be · +32 485 50 70 82
    • Sanne Stegen, Dr. · Principal investigator
    • Wim De Wilde, MSc · Principal investigator
    • Dirk Cambier, prof. dr. · Principal investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 4 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Oct 7, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Dec 20, 2026
CompletionEst.
Jan 30, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863219
Lead sponsor
University Ghent
Responsible party
Dirk Cambier (Senior Full Professor, Head of Department of Rehabilitation Sciences, University Ghent) — Principal investigator
First posted
Oct 7, 2026
Start date
Aug 1, 2026
Primary completion
Dec 20, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Wim De Wilde, MSc
Contact
Wim.dewilde@ugent.be
+32 472 57 58 08
Sanne Stegen, dr.
Contact
sanne.stegen@ugent.be
+32 485 50 70 82

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion